Matrix metalloproteinases in inflammatory demyelination: targets for treatment.
about
Myelin basic protein induces inflammatory mediators from primary human endothelial cells and blood-brain barrier disruption: implications for the pathogenesis of multiple sclerosisA macrophage cell model for selective metalloproteinase inhibitor designMMPs initiate Schwann cell-mediated MBP degradation and mechanical nociception after nerve damage.Cytokine regulation of MMP-9 in peripheral glia: implications for pathological processes and pain in injured nerve.Matrix metalloproteinase biology applied to vitreoretinal disorders.Inhibition of autoimmune encephalomyelitis by a tetracycline.The extracellular matrix in multiple sclerosis: an update.Cerebrospinal fluid matrix metalloproteinases are elevated in cerebral adrenoleukodystrophy and correlate with MRI severity and neurologic dysfunction.Matrix metalloproteinases, synaptic injury, and multiple sclerosisIntense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers.Matrix metalloproteinases and neuroinflammation in multiple sclerosis.Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies.TNFalpha-induced MMP-9 promotes macrophage recruitment into injured peripheral nerve.Mechanisms of disease: the blood-brain barrier.Crosstalk between oligodendrocytes and cerebral endothelium contributes to vascular remodeling after white matter injury.Effect of beta-dystroglycan processing on utrophin/Dp116 anchorage in normal and mdx mouse Schwann cell membrane.Matrix metalloproteinase-9 deficiency leads to prolonged foreign body response in the brain associated with increased IL-1beta levels and leakage of the blood-brain barrier.Multiple expression of matrix metalloproteinases in murine neurocysticercosis: Implications for leukocyte migration through multiple central nervous system barriers.Matrix metalloproteinase-12 deficiency worsens relapsing-remitting experimental autoimmune encephalomyelitis in association with cytokine and chemokine dysregulation.Bowman-Birk inhibitor suppresses autoimmune inflammation and neuronal loss in a mouse model of multiple sclerosis.Homocysteine decreases blood flow to the brain due to vascular resistance in carotid artery.Immunomodulatory treatment strategies in multiple sclerosis.Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned.White Matter Injury After Subarachnoid Hemorrhage: Role of Blood-Brain Barrier Disruption and Matrix Metalloproteinase-9.Regulation of homocysteine-induced MMP-9 by ERK1/2 pathway.The protease inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis.TACE mRNA expression in peripheral mononudear cells precedes new lesions on MRI in multiple sclerosis.Matrix metalloproteinase mediated degradation of basement membrane proteins in Trembler J neuropathy nerves.Certain forms of matrix metalloproteinase-9 accumulate in the extracellular space after microdialysis probe implantation and middle cerebral artery occlusion/reperfusion.Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients.Chronic cerebral hypoperfusion induces MMP-2 but not MMP-9 expression in the microglia and vascular endothelium of white matter.Differential MMP-2 and MMP-9 activity and collagen distribution in skeletal muscle from pacu (Piaractus mesopotamicus) during juvenile and adult growth phases.Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.Administration of SB203580, a p38 MAPK Inhibitor, Reduced the Expression of MMP9, and Relieved Neurologic Severity in the Experimental Autoimmune Neuritis (EAN) in Rats.Immunotherapy of multiple sclerosis.
P2860
Q28910423-AFF98789-9034-45B5-AA6D-B48E5DEE2BB3Q33680972-E97A3720-71F3-4348-BCB4-A46DC5D17674Q33834828-0A4B1869-5DF4-43D2-BCD7-C9E9FBFBDCE5Q33834853-FE30218F-074D-450E-B536-817BDE161362Q33933063-39154286-29F3-47BB-9D93-5E66A73AFD4DQ34113359-303DB691-F54E-4C04-BE12-0E30A8E7A35CQ34232680-BC2937C3-181E-43DD-8E5B-3004C3BB1B1CQ34491461-C77DD8E6-8563-46B0-B7BA-B9A9E03F5009Q34689554-869918F2-49E3-4B08-9981-75106753AA0FQ34718044-8472010C-C135-4E8C-9E42-E098B873DFB3Q35017633-C5CE6359-D92B-4F7F-AA75-2525ABC60B62Q35094706-8DF01A19-06C1-4E33-B432-7E30A85F83C6Q35606343-4EEA1CE9-9EA6-4ADA-82F6-9D26E44EF6B2Q35610735-BBC7138F-2AF8-4B10-8158-4B6B43FAEDDCQ35885998-C813FAD0-6180-4C08-8A85-80D979470FAFQ35987510-7BBFFC3A-6C43-45C0-BAB1-29F4FA1E0943Q36761698-4C9E8338-CF35-4180-83C4-BAF2D3308FCFQ36839585-BFA447D6-EC54-4855-A2AD-2AFF61F1F46BQ37150788-0EA9F4AC-7274-480F-827B-35E3540250DCQ37297572-06001EC3-7665-420F-A26E-7049AC6D9C46Q37347147-714E23EC-5C97-4FC1-AA26-E923567369A1Q37419041-9876A13A-A214-4405-B8BD-D98528225D99Q37634375-B213B32E-D086-4D8E-91E8-BEA69E2B33B4Q41555450-8B6C3BC4-1BD9-42EB-B23E-BF6B13167707Q46776194-E5FAB31E-047D-4F39-8558-8858BD015D51Q48293570-9C4B300B-DD58-4645-8005-41401ED992A9Q48429073-5D8AC3F3-7196-4754-8013-2084C8CC8EA6Q48451664-C37E85EB-F550-4D11-BD69-2C7A624F26E2Q48515189-D8A52A83-71D7-43D5-99DB-9C3337B89112Q48744549-C881211C-89E2-403B-9DB4-918D918E072AQ48824436-20C81A5E-A7C4-41B3-B43A-8B79E3A63E45Q50617342-7F7B1277-7E98-48E4-BAF2-208A292BD2B3Q50773267-1826C929-1365-4AAA-AED6-DB7E71664CC1Q53496273-AEEEDF68-046E-49E0-ABB5-71D66710AA54Q54502086-B9131DA0-8CBD-4ADB-AF83-93ACF6483838
P2860
Matrix metalloproteinases in inflammatory demyelination: targets for treatment.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Matrix metalloproteinases in inflammatory demyelination: targets for treatment.
@ast
Matrix metalloproteinases in inflammatory demyelination: targets for treatment.
@en
type
label
Matrix metalloproteinases in inflammatory demyelination: targets for treatment.
@ast
Matrix metalloproteinases in inflammatory demyelination: targets for treatment.
@en
prefLabel
Matrix metalloproteinases in inflammatory demyelination: targets for treatment.
@ast
Matrix metalloproteinases in inflammatory demyelination: targets for treatment.
@en
P356
P1433
P1476
Matrix metalloproteinases in inflammatory demyelination: targets for treatment.
@en
P2093
Kieseier BC
P356
10.1212/WNL.53.1.20
P407
P577
1999-07-01T00:00:00Z